[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Eom BW, Jung SY, Yoon H, Kook MC, Ryu KW, Lee JH, Kim YW: Gastric choriocarcinoma admixed with an alpha-fetoprotein-producing adenocarcinoma and separated adenocarcinoma. World J Gastroenterol; 2009 Oct 28;15(40):5106-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric choriocarcinoma admixed with an alpha-fetoprotein-producing adenocarcinoma and separated adenocarcinoma.
  • We report a case of gastric choriocarcinoma admixed with an alpha-fetoprotein (AFP)-producing adenocarcinoma.
  • A 70-year-old man was hospitalized for gastric cancer that was detected during screening by esophagogastroduodenoscopy (EGD).
  • Initial laboratory data showed the increased serum level of AFP and EGD revealed a 5-cm ulcerofungating mass in the greater curvature of the gastric antrum.
  • Histopathological evaluation confirmed double primary gastric cancer: gastric choriocarcinoma admixed with an AFP-producing adenocarcinoma and separated adenocarcinoma.
  • At 2 wk postoperatively, his human chorionic gonadotropin and AFP levels had reduced and six cycles of adjuvant chemotherapy were initiated.
  • [MeSH-major] Adenocarcinoma / drug therapy. Choriocarcinoma / diagnosis. Stomach Neoplasms / diagnosis. alpha-Fetoproteins / biosynthesis
  • [MeSH-minor] Aged. Chorionic Gonadotropin / metabolism. Gastrectomy. Humans. Lymph Nodes / pathology. Male. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Pathol Jpn. 1993 Nov;43(11):654-61 [7508672.001]
  • [Cites] Gastroenterol Jpn. 1992 Dec;27(6):785-91 [1281798.001]
  • [Cites] Arch Pathol Lab Med. 1995 Nov;119(11):1075-9 [7487411.001]
  • [Cites] Am J Gastroenterol. 1996 May;91(5):1045-6 [8633553.001]
  • [Cites] Cancer. 1953 Mar;6(2):319-26 [13032923.001]
  • [Cites] Am J Surg. 1960 Aug;100:224-33 [14436952.001]
  • [Cites] Gastric Cancer. 2005;8(3):178-85 [16086121.001]
  • [Cites] Gastric Cancer. 2002;5(2):112-7 [12111588.001]
  • [Cites] Diagn Mol Pathol. 2001 Sep;10(3):161-5 [11552718.001]
  • [Cites] Surg Today. 2007;37(11):995-9 [17952534.001]
  • [Cites] Dig Surg. 2002;19(5):359-65; discussion 365 [12435906.001]
  • [Cites] Kurume Med J. 2003;50(1-2):63-6 [12971266.001]
  • [Cites] Am J Gastroenterol. 1988 Oct;83(10):1172-5 [3048084.001]
  • [Cites] Ann Thorac Surg. 1992 Jan;53(1):151-2 [1370196.001]
  • [Cites] Am J Gastroenterol. 1992 Mar;87(3):321-5 [1371637.001]
  • [Cites] J Urol. 1994 Sep;152(3):958-60 [7519684.001]
  • (PMID = 19860007.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / alpha-Fetoproteins
  • [Other-IDs] NLM/ PMC2768893
  •  go-up   go-down


2. Park JM, Chi KC: Unresectable gastric cancer with gastric outlet obstruction and distant metastasis responding to intraperitoneal and folfox chemotherapy after palliative laparoscopic gastrojejunostomy: report of a case. World J Surg Oncol; 2010;8:109
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unresectable gastric cancer with gastric outlet obstruction and distant metastasis responding to intraperitoneal and folfox chemotherapy after palliative laparoscopic gastrojejunostomy: report of a case.
  • BACKGROUND: Gastric outlet obstruction (GOO) caused by unresectable gastric cancer is a challenging aspect of patient care.
  • There have been no reports involving patients with obstructing gastric cancer and several incurable factors curatively treated by multimodal treatments.
  • CASE PRESENTATION: We report a case of 55-year-old man who was diagnosed with a poorly differentiated adenocarcinoma in the pre-pyloric antrum with GOO by gastroscopy.
  • An abdominal computed tomography (CT) scan revealed thickening of the gastric wall and adjacent fat infiltration, and a large amount of food in the stomach suggesting a passage disturbance, enlarged lymph nodes along the common hepatic and left gastric arteries, and multiple hepatic metastases.
  • On the 3rd and 12th days after surgery, he received intraperitoneal chemotherapy with 40 mg of docetaxel and 150 mg of carboplatin.
  • Simultaneously, combined chemotherapy with 85 mg/m2 of oxaliplatin for the 1st day and 600 mg/m2 of 5-FU for 2 days (FOLFOX regimen) was administered from the 8th post-operative day.
  • CONCLUSION: Combination chemotherapy with systemic and intraperitoneal chemotherapy following laparoscopic bypass surgery showed marked efficacy in the treatment for unresectable advanced gastric cancer with GOO.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastric Bypass. Gastric Outlet Obstruction. Laparoscopy. Stomach Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Fluorouracil / therapeutic use. Humans. Injections, Intraperitoneal. Leucovorin / therapeutic use. Male. Middle Aged. Organoplatinum Compounds / therapeutic use. Palliative Care. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2000 Feb;58(2):96-107 [10705236.001]
  • [Cites] Gastrointest Endosc. 2010 Mar;71(3):490-9 [20003966.001]
  • [Cites] Br J Cancer. 2005 Jul 25;93(2):190-4 [16012522.001]
  • [Cites] Gastric Cancer. 2006;9(2):136-9 [16767370.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):661-5 [16621433.001]
  • [Cites] Am J Clin Oncol. 2006 Aug;29(4):371-5 [16891864.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3953-8 [16921048.001]
  • [Cites] Eur J Surg Oncol. 2006 Dec;32(10):1105-9 [16930932.001]
  • [Cites] Int J Clin Oncol. 2006 Dec;11(6):471-4 [17180517.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Am J Clin Oncol. 2008 Jun;31(3):259-63 [18525305.001]
  • [Cites] Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1895-8 [19102417.001]
  • [Cites] Eur J Cancer. 2009 Jan;45(2):228-47 [19097774.001]
  • [Cites] J Surg Oncol. 2009 Sep 1;100(3):215-21 [19235783.001]
  • [Cites] J Surg Oncol. 2009 Sep 15;100(4):311-6 [19697437.001]
  • [Cites] Ann Surg Oncol. 2009 Dec;16(12):3227-36 [19777180.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • (PMID = 21167074.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  • [Other-IDs] NLM/ PMC3014937
  •  go-up   go-down


3. Thong-Ngam D, Tangkijvanich P, Lerknimitr R, Mahachai V, Theamboonlers A, Poovorawan Y: Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol; 2006 Jul 28;12(28):4473-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic role of serum interleukin-18 in gastric cancer patients.
  • AIM: To determine the current status in various aspects of gastric cancer patients and to find out the clinical correlation with prognostic role of serum interleukins in Thai patients.
  • Gastric cancer was histologically proven in 51 patients and gastric ulcer in 17 patients.
  • A total of 35.3% gastric cancer patients and 6.3% of gastric ulcer patients were smokers (P = 0.029).
  • Moreover, 32.4% of gastric cancer patients and 6.3% of gastric ulcer patients were alcoholic drinkers (P = 0.044).
  • Lesion location was pyloric-antrum in 39.4%, gastric body in 39.4%, upper stomach in 12.2% and entire stomach in 6.1% of the patients.
  • The poorly-differentiated adenocarcinoma was the most common pathologic finding (60.7%).
  • Surgical treatment was performed in 44.1% patients (total gastrectomy in 5.9%, subtotal gastrectomy in 32.4% and palliative bypass surgery in 5.9%).
  • Systemic chemotherapy was given as an adjuvant therapy in 8.8% patients.
  • The mean survival time was 13.03 +/- 9.75 mo.
  • The IL-18 level in gastric cancer patient group (58.54 +/- 43.96 pg/mL) was significantly higher than that in gastric ulcer patient group (30.84 +/- 11.18 pg/mL) (P = 0.0001) (95% CI was 42.20, 13.19).
  • The cut point of IL-18 for diagnosis of gastric cancer was 40 pg/mL, the positive predictive value was 92.31%.
  • The IL-6 level in gastric cancer patients with distant metastasis (20.21 +/- 9.37 pg/mL) was significantly higher than that in those with no metastasis (10.13 +/- 7.83 pg/mL) (P = 0.037) (95% CI was 19.51, 0.65).
  • The role of IL-10 and IL-12 levels in gastric cancer patients was to provide data with no significant difference.
  • CONCLUSION: These findings demonstrate that serum IL-6 and IL-18, but not IL-10 and IL-12 levels may be the useful biological markers of clinical correlation and prognostic factor in patients with gastric cancer.
  • Moreover, IL-18 could serve as a diagnostic marker for gastric cancer with a high positive predictive value.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastric Cancer. 2005;8(2):124-31 [15864720.001]
  • [Cites] Gastric Cancer. 2005;8(2):86-94 [15864715.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2661-9 [10914707.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4838-44 [10987295.001]
  • [Cites] Annu Rev Immunol. 2001;19:423-74 [11244043.001]
  • [Cites] J Med Assoc Thai. 2001 Apr;84(4):475-82 [11460956.001]
  • [Cites] J Clin Gastroenterol. 2002 Apr;34(4):416-20 [11907352.001]
  • [Cites] J Surg Res. 2004 Feb;116(2):277-87 [15013367.001]
  • [Cites] Ann Surg. 1987 Jan;205(1):1-8 [3800453.001]
  • [Cites] Cytokine. 1991 May;3(3):212-23 [1653054.001]
  • [Cites] Int J Cancer. 1991 Oct 21;49(4):513-9 [1917151.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1731-5 [8448737.001]
  • [Cites] Adv Immunol. 1993;54:1-78 [8379461.001]
  • [Cites] Ann Surg. 1993 Nov;218(5):583-92 [8239772.001]
  • [Cites] Int J Cancer. 1993 Dec 2;55(6):891-903 [8253525.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jul-Aug;3(5):445-51 [7920213.001]
  • [Cites] Dig Dis. 1994 Sep-Oct;12(5):276-89 [7882548.001]
  • [Cites] Nature. 1995 Nov 2;378(6552):88-91 [7477296.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):281-91 [8658212.001]
  • [Cites] Eur J Cancer Prev. 1996 Oct;5(5):405-8 [8972278.001]
  • [Cites] J R Soc Med. 1996 Dec;89(12):674-8 [9014876.001]
  • [Cites] Gut. 1997 Jun;40(6):739-44 [9245927.001]
  • [Cites] Jpn J Cancer Res. 1997 Oct;88(10):953-8 [9414656.001]
  • [Cites] J Clin Invest. 1998 Mar 15;101(6):1441-52 [9502787.001]
  • [Cites] Annu Rev Immunol. 1998;16:495-521 [9597139.001]
  • [Cites] Br Med Bull. 1998;54(1):139-50 [9604438.001]
  • [Cites] J Leukoc Biol. 1998 Jun;63(6):658-64 [9620656.001]
  • [Cites] J Biol Regul Homeost Agents. 1998 Jan-Jun;12(1-2):38-41 [9677534.001]
  • [Cites] J Clin Immunol. 1999 Jan;19(1):1-11 [10080100.001]
  • [Cites] Eur Cytokine Netw. 2000 Mar;11(1):15-26 [10705295.001]
  • (PMID = 16874857.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-18; 0 / Interleukin-6; 130068-27-8 / Interleukin-10; 187348-17-0 / Interleukin-12
  • [Other-IDs] NLM/ PMC4125632
  •  go-up   go-down


Advertisement
4. Shindo Y, Yoshino S, Maeda Y, Suzuki N, Oka M: [A case of unresectable advanced gastric cancer successfully treated with chemotherapy after gastrojejunostomy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2487-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of unresectable advanced gastric cancer successfully treated with chemotherapy after gastrojejunostomy].
  • We report a patient with unresectable advanced gastric cancer who was successfully treated with chemotherapy after gastrojejunostomy.
  • Abdominal enhanced CT revealed a gastric wall thickening and swelling of lymph nodes in the lesser curvature.
  • Upper gastrointestinal endoscopy showed a gastric cancer in the antrum of the stomach.
  • After the operation, intake therapy of 80-100 mg S-1 was started for four weeks followed by two weeks rest as one course.
  • After 2 courses of the therapy, abdominal enhanced CT showed a partial response of the lymph nodes.
  • This case suggested that S-1 chemotherapy after gastrojejunostomy was effective for unresectable advanced gastric cancer because of the long-term survival and an improvement of the patient's quality of life.
  • [MeSH-major] Adenocarcinoma / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Drug Combinations. Gastric Bypass. Humans. Male. Middle Aged. Oxonic Acid / therapeutic use. Tegafur / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224615.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


5. Ishikawa T, Nomura K, Baba Y, Hayashi S, Oota H, Yoshida T, Kamimura T: [A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy]. Gan To Kagaku Ryoho; 2003 Aug;30(8):1151-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy].
  • There have been few effective chemotherapeutic regimens for advanced gastric cancer with liver and intra-abdominal lymph node metastasis.
  • Gastroendoscopy showed a type 4 advanced gastric cancer in the antrum of the stomach.
  • Histological study of biopsy specimens from the tumor revealed poorly differentiated adenocarcinoma.
  • Examination by computed tomography and ultrasonography showed swollen paraaortic lymph nodes and liver metastasis.
  • He was diagnosed as having advanced gastric cancer with liver and lymph node metastasis.
  • Furthermore, he was administered tegafur/uracil (400 mg/day) 5 days weekly as pharmacokinetic modulating chemotherapy (PMC).
  • After ten courses of treatment with PMC, the liver and lymph node metastases were reduced in size.
  • This therapy was considered to be an effective treatment for advanced gastric cancer with liver and lymph node metastasis.
  • The theoretical purpose of hypertensive chemotherapy used together with injection of angiotensin-II is to increase the delivery of anticancer drug to the target tumor tissue by increasing the blood flow in the tumor.
  • We conclude that this chemotherapy is effective in cases of advanced gastric cancer with liver and lymph node metastasis from the viewpoints of toxicities, antitumor effect and QOL of the patient.
  • [MeSH-major] Angiotensin II / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Methotrexate / administration & dosage. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / secondary

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12938272.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11128-99-7 / Angiotensin II; 1548R74NSZ / Tegafur; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


6. Gisbert JP: [Helicobacter pylori-related diseases: dyspepsia, ulcer and gastric cancer]. Gastroenterol Hepatol; 2008 Oct;31 Suppl 4:18-28
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Helicobacter pylori-related diseases: dyspepsia, ulcer and gastric cancer].
  • Several strains of H. pylori frequently infect the same patient, and consequently samples for culture should be obtained from the gastric antrum and body.
  • The test-and-treat strategy in dyspepsia is as effective as empirical antisecretory therapy and is probably cheaper.
  • The benefit of eradication therapy in patients with uninvestigated dyspepsia, although small, seems to be lasting.
  • Patients with H. pylori-negative bleeding ulcers have a high probability of hemorrhagic recurrence and should therefore receive maintenance antisecretory therapy. H. pylori eradication reduces the incidence of gastric adenocarcinoma, which could warrant a screening and treatment strategy for this infection in the general population in high risk areas. H. pylori infection should be eradicated in patients undergoing endoscopic mucosal resection for early gastric cancer.
  • To prevent the development of gastric cancer, eradication therapy should be administered early, before gastric atrophy develops. H. pylori-negative and H. pylori-positive gastric lymphomas have an equally favorable prognosis.
  • New diagnostic techniques have been developed: the ultra-rapid urease test, a simpler 14C-urea breath test, and an ELISA method for rapid bacterial susceptibility determination.
  • "Sequential" therapy is more effective and cheaper than classical triple-drug therapy, although the superiority of administering therapy sequentially rather than concomitantly has not been established.
  • In penicillin-allergic patients, a combination with levofloxacin and clarithromycin is a promising alternative in rescue therapy.
  • Second-line rescue therapy with levofloxacin is effective and is also simpler and better tolerated than quadruple-drug therapy.
  • Third-line treatment with levofloxacin is also a promising alternative.
  • Even after the failure of three previous treatments, a fourth empirical rescue therapy (with levofloxacin or rifabutin) can be effective in more than half of patients.
  • The annual recurrence rate of H. pylori infection is approximately 3% in developed countries and is higher than 10% in developing countries.


7. Katsube T, Kikuchi T, Konnno S, Murayama M, Kobayashi R, Kuhara K, Yoshimatsu K, Shiozawa S, Shimakawa T, Naritaka Y, Ogawa K, Hagiwara S, Aiba M: Subdural hematoma associated with dural metastasis of gastric carcinoma: report of two cases. Anticancer Res; 2007 Nov-Dec;27(6C):4339-44
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subdural hematoma associated with dural metastasis of gastric carcinoma: report of two cases.
  • We treated two cases of a subdural hematoma associated with dural metastasis of gastric cancer, from which both patients died.
  • Case 1: A 60-year-old female patient was hospitalized with a diagnosis of type 4 gastric cancer of the antrum.
  • A head computed tomography (CT) scan revealed a subdural hematoma with midline shift.
  • Case 2: A 73-year-old man was diagnosed with type 4 gastric cancer and a total gastrectomy plus splenectomy were performed together with dissection of the N1 and N2 lymph node groups (D2 dissection) in March 2006 (T3, N2, P0, H0, INFgamma, ly3, v0, por2).
  • Postoperative adjuvant chemotherapy was performed using oral TS-1; following tests revealed no recurrence in the abdomen.
  • The dural biopsy of the two cases revealed adenocarcinoma noted in the dural blood vessel.
  • Special staining revealed CEA-positive adenocarcinoma, and a diagnosis of the dural metastasis of gastric cancer was made.
  • However, DIC developed concurrently, and the patients died on the 13th and 14th postoperative day, respectively.
  • [MeSH-major] Adenocarcinoma / secondary. Dura Mater / pathology. Hematoma, Subdural, Intracranial / etiology. Meningeal Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18214041.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


8. Leung WK, Ng EK, Chan FK, Chan WY, Chan KF, Auyeung AC, Lam CC, Lau JY, Sung JJ: Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. Clin Cancer Res; 2006 Aug 1;12(15):4766-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial.
  • PURPOSE: Gastric cancer and its premalignant gastric lesion, intestinal metaplasia (IM), frequently express cyclooxygenase-2 (COX-2) at high levels.
  • We tested whether long-term use of specific COX-2 inhibitors regress gastric IM.
  • Endoscopy was done at baseline, at the end of year 1, and at the end of year 2, with multiple biopsies taken from the antrum and corpus.
  • The proportion of subjects with the regression of IM did not differ significantly between rofecoxib and placebo groups (antrum, 24.5% versus 26.9%; P = 0.74; corpus, 4.3% versus 2.2%; P = 0.68).
  • There was also no significant difference in the severity of IM between the two treatment groups (P >or= 0.3).
  • CONCLUSIONS: There was no trend to suggest that treatment with rofecoxib for 2 years resulted in the regression of gastric IM.
  • Although our findings cast doubt on the reversibility of gastric IM by COX-2 inhibitor, further studies are needed to establish the role of COX-2 inhibitors in different stages of gastric carcinogenesis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Gastrointestinal Neoplasms / drug therapy. Lactones / administration & dosage. Metaplasia / drug therapy. Sulfones / administration & dosage
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Double-Blind Method. Drug Administration Schedule. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Placebos. Prospective Studies. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16899628.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Lactones; 0 / Placebos; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib
  •  go-up   go-down


9. Mimatsu K, Oida T, Kawasaki A, Kano H, Kuboi Y, Aramaki O, Amano S: Laparoscopic-assisted stomach-partitioning gastrojejunostomy for the palliation of gastric outlet obstruction from antral gastric cancer. Surg Laparosc Endosc Percutan Tech; 2009 Jun;19(3):e76-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic-assisted stomach-partitioning gastrojejunostomy for the palliation of gastric outlet obstruction from antral gastric cancer.
  • Conventional gastrojejunostomy is performed for gastric outlet obstruction; however, we have experience of some patients for whom oral intake was not adequately restored.
  • Open stomach-partitioning gastrojejunostomy is a useful technique for the relief of unresectable and obstructing antral gastric cancers.
  • We herein report the successful laparoscopic application of this technique in 2 patients: a 62-year-old male and a 65-year-old female with obstructing antral gastric cancer.
  • Chemotherapy by oral administration was possible for each patient.
  • There was no recurrence of the gastric outlet obstruction in either patient up until they died 6 and 10 months after surgery.
  • Laparoscopic stomach-partitioning gastrojejunostomy is a safe and useful technique for treating unresectable and obstructing antral gastric cancer, allowing the possibility of adequate oral intake and permitting the administration of anticancer drugs.
  • [MeSH-major] Adenocarcinoma / surgery. Gastric Bypass / methods. Gastric Outlet Obstruction / surgery. Laparoscopy / methods. Palliative Care / methods. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Endoscopy, Gastrointestinal. Fatal Outcome. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging / methods. Pyloric Antrum

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542834.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Kadono M, Iwasaki Y, Ohashi M, Iwanaga T, Ohinata R, Takahashi K, Yamaguchi T, Matsumoto H, Nakano D: [An effective treatment by chemotherapy with S-1 and CDDP intraperitoneal administration for the peritoneal dissemination of gastric cancer--a case report]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2442-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An effective treatment by chemotherapy with S-1 and CDDP intraperitoneal administration for the peritoneal dissemination of gastric cancer--a case report].
  • The most common treatment for patients of peritoneal dissemination of gastric cancer is a systemic chemotherapy, but the prognosis of these patients is very poor.
  • For these diseases, some have reported the usefulness of intraperitoneal chemotherapy with cisplatin (CDDP), because of the direct cytotoxicity.
  • Here, we report an effective treatment by chemotherapy with S-1 plus CDDP, intraperitoneal administration for the patients of peritoneal dissemination of gastric cancer.
  • Upper gastrointestinal endoscopy showed a large type 3 gastric cancer from the cardia to antrum.
  • After 10 courses, he was treated with S-1 alone because he had an allergic reaction of CDDP.
  • Intraperitoneal chemotherapy may be a promising treatment for the patients who have peritoneal dissemination from gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Administration, Oral. Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Drug Combinations. Humans. Infusions, Parenteral. Male. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224600.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Shioiri T, Inoue S, Kusano T, Umekita N, Kitamura M, Warabi M, Kawahara Y: [A case of advanced gastric cancer responding to neoadjuvant TS-1/CDDP chemotherapy]. Gan To Kagaku Ryoho; 2005 Sep;32(9):1327-30
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer responding to neoadjuvant TS-1/CDDP chemotherapy].
  • Upper gastrointestinal endoscopy and X-ray examination of the stomach revealed type 3 cancer in the gastric antrum, extending to the middle body.
  • It was about 9 cm in diameter, and the biopsy specimen revealed moderately differentiated tubular adenocarcinoma.
  • For this gastric cancer, clinical Stage IIIA (cT3N1HOPOMO), neoadjuvant chemotherapy with TS-1/CDDP was planned.
  • TS-1 (120 mg/day) was orally administered for 3 weeks followed by a drug-free-2-week period as the first course, and 93 mg (60 mg/m2) of CDDP administered by intravenous drip on day 8.
  • An upper GI series revealed 33% reduction of gastric cancer, and laboratory studies CEA and CA 19-9 showed normal values.
  • One month after the second course of chemotherapy, total gastrectomy, splenectomy and lymph node dissection D2 were performed.
  • The pathological specimens showed no cancer cells in the surgically obtained stomach and lymph nodes, so the histological effect was Grade 3.
  • TS-1/CDDP chemotherapy produced a high response in this case, and it may be useful as neoadjuvant chemotherapy for advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Nodes / pathology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Gastrectomy. Humans. Infusions, Intravenous. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Remission Induction. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184934.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Wilkinson NW, Howe J, Gay G, Patel-Parekh L, Scott-Conner C, Donohue J: Differences in the pattern of presentation and treatment of proximal and distal gastric cancer: results of the 2001 gastric patient care evaluation. Ann Surg Oncol; 2008 Jun;15(6):1644-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the pattern of presentation and treatment of proximal and distal gastric cancer: results of the 2001 gastric patient care evaluation.
  • BACKGROUND: While the overall incidence of gastric cancer has declined in the United States of America, the incidence of proximal gastric cancers has increased.
  • The purpose of this analysis was to highlight key differences between proximal and distal gastric cancer as they relate to presentation and treatment.
  • METHODS: Data on 6,099 patients diagnosed with gastric adenocarcinoma were collected as a patient care evaluation under the auspices of the American College of Surgeons Commission on Cancer.
  • RESULTS: The proximal cancer group included 1,924 patients (87% cardia, 13% fundus) and the distal cancer group included 1,311 patients (85% antrum, 15% pylorus).
  • Proportionately, proximal cancer cases were male (P < 0.01), younger (P < 0.01), and White (P < 0.01); whereas, distal gastric cancer cases were Black (P < 0.01), Hispanic (P < 0.01), and Asian (P = 0.01).
  • Surgery alone (without adjuvant chemotherapy or radiation) was utilized more frequently in distal disease (39.5%) compared to proximal disease (25.7%) (P < 0.01).
  • Preoperative adjuvant therapy was utilized more frequently in proximal disease (41.7%) compared to distal disease (2.1%) (P < 0.01).
  • CONCLUSIONS: The populations that developed proximal verses distal gastric cancer differed with respect to sex, age, and racial background.
  • Cancer-directed treatments also differed based upon tumor location.
  • Understanding these differences may someday enable us to identify important high-risk populations, prevention strategies, and ultimately best treatment strategies.
  • [MeSH-major] Adenocarcinoma / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392661.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Yamada E, Ninomiya M, Nishizaki M, Sasaki H, Takakura N: [A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil]. Gan To Kagaku Ryoho; 2007 Jun;34(6):911-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil].
  • Endoscopic findings showed Type 3 gastric cancer with pyloric stenosis.
  • Intraperitoneal administration of weekly CDDP 10 mg/body was in vain, and combined chemotherapy of paclitaxel and 5-fluorouracil was carried out.
  • Endoscopic examination showed improvement in narrowing of the antrum.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / complications. Quality of Life. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Fluorouracil / administration & dosage. Gastroscopy. Humans. Male. Middle Aged. Neoplasm Invasiveness. Paclitaxel / administration & dosage. Pancreatic Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pyloric Stenosis / pathology. Survivors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17565255.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Power DG, Jhawer M, Feilchenfeldt JW, Kelsen DP, Shah MA: Metastatic gastroesophageal cancer and long-term survival. J Clin Oncol; 2009 May 20;27(15_suppl):4560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic gastroesophageal cancer and long-term survival.
  • : 4560 Background: Despite modest therapeutic improvements, resistance to systemic chemotherapy develops in most pts with advanced gastric/GEJ (GE) adenocarcinoma.
  • However, a subgroup of pts(5-10%) have substantial benefit from chemotherapy, living >2 years.
  • We describe clinicopathological characteristics of a large cohort of long term survivors(LTS) with metastatic GE adenocarcinoma.
  • METHODS: Our institutional database of pts with GE adenocarcinoma who received chemotherapy between 1999-2008 identified 103 pts with metastatic disease (M1) surviving >2 years from M1.
  • We evaluated clinicopathologic characteristics for correlation of LTS with chemotherapy.
  • RESULTS: From Jan 1999-2008, 1,140 pts with metastatic GE cancer received systemic therapy.
  • From the time of M1, 103 pts (9%) lived >2 yrs.
  • Tumors were located at GEJ/cardia (n=52), body/fundus (n=29), antrum/pylorus (n=22), and were mainly poorly differentiated (n=61).
  • 77 pts presented with M1 and 26 developed recurrence after resection.
  • 52 pts received 2-3 treatment regimens, range 1-7.
  • Common regimens were docetaxel/fluoropyrimidine (26), cisplatin/irinotecan (21), and DCF (11); intraperitoneal chemotherapy (5).
  • No distinct clinicopathologic correlates were identified as associated with prolonged survival with systemic chemotherapy.
  • CONCLUSIONS: Although systemic chemotherapy has modestly improved survival in advanced GE cancers, long term control is possible.
  • We are now exploring tumor and normal tissue from LTS versus matched controls (survival <1 year) for molecular/genomic correlates for LTS No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963060.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Takada J, Watanabe K, Kuraya D, Kina M, Hayashi S, Hamada H, Katsuki Y: [Preoperative S-1/CDDP combination chemotherapy was effective in a case of local advanced gastric cancer]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2451-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative S-1/CDDP combination chemotherapy was effective in a case of local advanced gastric cancer].
  • INTRODUCTION: The prognosis of type 4 advanced gastric cancer is extremely poor, even the use of multidisciplinary treatment cannot provide satisfactory results.
  • Presented here is a case of highly advanced gastric cancer in which preoperative chemotherapy was effective and resection possible.
  • Visual inspection showed a lesion extending from the greater curvature of the fundus to the antrum.
  • Type 4 advanced gastric cancer was strongly suspected.
  • Biopsy samples taken from the antral lesser curvature and from the ulcer border on the upper anterior wall of the body were diagnosed as Group V, adenocarcinoma.
  • Abdominal CT revealed no hepatic mass, but overall thickening of the gastric wall was noticeable and the lymph nodes in the area of the lesser curvature of the stomach and celiac artery were identified.
  • Abdominal ultrasound showed an overall thickening of the gastric wall, and invasion into a portion of the left hepatic lobe and pancreas was suspected.
  • TREATMENT: Because of gastric cancer with suspected invasion of the left hepatic lobe and pancreas, it was decided to perform preoperative chemotherapy (S-1 + CDDP) and then perform a total gastrectomy.
  • Only scarring in the body and antrum was found, the enlargement was greatly reduced and visual inspection revealed no esophageal infiltration.
  • Biopsy samples were taken from 2 sites, the body center on the lesser curvature side and the greater curvature of the antrum.
  • Scar-like fibrosis was significant and it was not possible to distinguish an increase in poorly differentiated adenocarcinoma.
  • Abdominal CT showed a reduction in gastric wall thickening.
  • These findings showed preoperative chemotherapy to be effective.
  • Following the chemotherapy, a total gastrectomy in addition to splenectomy and cholecystectomy were performed.
  • Histopathological findings showed MLU, type 5, approx.
  • 8.5 × 13 cm, poorly differentiated adenocarcinoma (por 2), INF γ, sci, pT2 (SS), ly2, v0, pN2 (#1: 2/8, #6: 1/6, #11p: 2/5), pPM (-), pDM (-), Stage IIIA.
  • Along with the formation of fibrous scar tissue, an invasive growth of por 2 poorly differentiated adenocarcinoma was found from the submucosal layer to just beneath the serosal layer.
  • Therapeutic effect of the chemotherapy was Grade 2.
  • Post operative S-1 + CDDP was begun but nausea developed and S-1 was reduced.
  • Because of a decrease of neutrophils and nausea, the therapy was changed to UFT.
  • CONCLUSION: Preoperative chemotherapy (S-1 + CDDP) is a therapy which shows promise in reducing tumor size even in highly advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Combinations. Female. Gastrectomy. Humans. Middle Aged. Oxonic Acid / administration & dosage. Preoperative Period. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224603.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Maksimovic S: Double tract reconstruction after total gastrectomy in patients with gastric cancer: our experience. Med Arh; 2010;64(2):116-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double tract reconstruction after total gastrectomy in patients with gastric cancer: our experience.
  • PURPOSE: Gastric cancer (GC) remains one of the most frequent cancers worldwide.
  • The double tract (DT) method is the optimal reconstruction procedure aftertotal gastrectomy for patients with gastric cancer.
  • Tumor diffused in the sections of stomach in 37 cases: cardia and body in 14 cases, body and antrum in 16 cases, and in only body of stomach in 7 cases.
  • In the pathological examination, the tumors of 34 patients were diagnosed as adenocarcinoma, 2 as malignant lymphoma, and i as leiomyosarcoma.
  • CONCLUSIONS: The benefits of this method are (1) a simple procedure;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514781.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


17. Koyasaki N, Matsumura A, Kamata T, Kanno M: [A case of advanced gastric carcinoma with liver metastasis with no recurrence and long survival by means of surgery and postoperative chemotherapy]. Gan To Kagaku Ryoho; 2002 Apr;29(4):611-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric carcinoma with liver metastasis with no recurrence and long survival by means of surgery and postoperative chemotherapy].
  • A 69-year-old man was diagnosed with type 2 advanced gastric carcinoma at the antrum of the stomach with liver metastasis (S8) in July 1995.
  • Distal partial gastrectomy was performed with combined D2 lymphadenectomy and partial hepatectomy.
  • Fifty-six courses of low-dose chemotherapy with CDDP and 5-FU were administered from the time of surgery to March 1997.
  • Aggressive treatment combining surgery and long-term postoperative chemotherapy is potentially useful in contributing to long survival in cases of advanced gastric cancer with liver metastasis.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Fluorouracil / administration & dosage. Gastrectomy. Hepatectomy. Humans. Lymph Node Excision. Male. Survivors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11977549.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


18. Yamamoto S, Tanaka Y, Ito T, Aono T, Morimoto Y, Kitagawa T, Kurihara Y: Weekly paclitaxel for a patient with advanced gastric cancer. Gastric Cancer; 2003;6(2):117-21
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly paclitaxel for a patient with advanced gastric cancer.
  • A 56-year-old woman diagnosed with gastric cancer was admitted to our hospital for operation on May 15, 2001.
  • The tumor formed a large mass from the antrum to the head of the pancreas, and cancer cells were detected in the ascitic fluid microscopically.
  • On July 17, a new regimen, of 4-week courses of chemotherapy, with weekly administrations of 65 mg/m2 of paclitaxel, along with premedication for 3 weeks, followed by 1 week of rest, was started.
  • After paclitaxel was started, gastric fiberscopy and computed tomography (CT) scan showed reduction of the tumor.
  • Neuropathy was slight and no treatment was needed.
  • Now, after 1 year, 11 courses of chemotherapy have been administered at the outpatient clinic.
  • These results suggest weekly administration of paclitaxel to be a promising treatment for advanced gastric cancer with peritoneal dissemination.
  • The therapeutic efficacy should be confirmed by further clinical trials.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Female. Gastric Mucosa / drug effects. Gastric Mucosa / pathology. Gastric Mucosa / radiography. Humans. Middle Aged. Radiography, Abdominal. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12884850.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 14
  •  go-up   go-down


19. Yang CK, Zhao WJ, Dai QB, Zhang HH, Zheng W: [Clinical characteristics, diagnosis and treatment of hepatoid adenocarcinoma of the stomach]. Zhonghua Wei Chang Wai Ke Za Zhi; 2007 May;10(3):245-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics, diagnosis and treatment of hepatoid adenocarcinoma of the stomach].
  • OBJECTIVE: To investigate the clinical characteristics,diagnosis and treatment of hepatoid adenocarcinoma of the stomach.
  • METHODS: Clinical data of 13 hepatoid adenocarcinomas of the stomach, collected from 201 cases of gastric cancer, were analyzed retrospectively.
  • RESULTS: Of the 201 gastric carcinomas, there were 13 AFP-producing adenocarcinomas of the stomach, the positive rate was 6.5%.
  • Of the 13 hepatoid adenocarcinomas of the stomach, 10 cases were in gastric antrum and 10 cases were poorly differentiated.
  • The metastasis rates of liver and lymph node in hepatoid adenocarcinoma of stomach were higher than those in non-hepatoid adenocarcinoma of stomach.
  • The treatment of hepatoid adenocarcinoma of stomach depended mainly on radical resection, and adjuvant chemotherapy was needed.The prognosis of hepatoid adenocarcinoma of stomach was poor.
  • CONCLUSION: Hepatoid adenocarcinoma of the stomach has its own special tumor biological behavior and poor prognosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Gastrectomy. Humans. Male. Middle Aged. Retrospective Studies. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520383.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


20. Fukuda Y, Fujio N, Ihara T, Takatori H, Tsukazaki T, Koyama I, Tsukazaki Y, Osugi H: [A case of advanced gastric cancer with direct invasion of the transverse colon responding to paclitaxel/5'-DFUR combined therapy]. Gan To Kagaku Ryoho; 2005 Nov;32(12):1945-8
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with direct invasion of the transverse colon responding to paclitaxel/5'-DFUR combined therapy].
  • A 50-year-old man was diagnosed with non-resectable scirrhous gastric cancer of antrum accompanied with colon ileus due to direct invasion of the transverse colon.
  • As the ileus improved after cecostomy, chemotherapy with TS-1/cisplatin(CDDP) was performed.
  • Because of no response, 4 cycles of paclitaxel (PTX)/doxifluridine (5'-DFUR) therapy was performed as second-line chemotherapy.
  • Though 2 cycles of PTX/5'-DFUR therapy was performed postoperatively and the patient's postoperative condition was good, he was suffering from carcinomatous peritonitis complicated by ileus and obstructive jaundice 4 months after operation.
  • PTX/5'-DFUR therapy, which has only slight complications, may be useful for patients with recurrent gastric cancer who had been treated with 5-FU administration as first-line chemotherapy.
  • But the future problem was how to control dissemination after surgery in a resectable case after chemotherapy.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colon, Transverse / pathology. Colonic Neoplasms / pathology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Floxuridine / administration & dosage. Humans. Ileus / etiology. Male. Middle Aged. Neoplasm Invasiveness. Paclitaxel / administration & dosage. Peritoneal Neoplasms / secondary. Quality of Life

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282732.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


21. Hashimoto K, Suzuki M: [A case of metachronous liver metastasis from gastric cancer treated with multidisciplinary therapy including hepatectomy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2324-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metachronous liver metastasis from gastric cancer treated with multidisciplinary therapy including hepatectomy].
  • A 73-year-old man underwent a distal gastrectomy with dissection of D2 lymph nodes for type 2 gastric cancer at the front wall of pyloric antrum in June 2006 (Pathological finding was moderately differentiated adenocarcinoma, T2, N0, H0, P0, M0, fStage IB).
  • Although he was given UFT and PSK for postoperative adjuvant therapy, MRI showed a liver metastasis at segment 6 of the liver in June 2007.
  • After hepatectomy, 5 courses of S-1 as adjuvant therapy were administered.
  • After 3 courses of S-1 and CDDP, we performed radiofrequency ablation (RFA) therapy and a good cauterization effect was obtained.
  • We experienced a case of metachronous liver metastasis from gastric cancer treated with multidisciplinary therapy that was beneficial for a long term survival.
  • [MeSH-major] Adenocarcinoma / pathology. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Neoplasms, Second Primary / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Catheter Ablation. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Combinations. Humans. Male. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037410.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Raderer M, Püspök A, Stummvoll G, Längle F, Chott A: Early cancer of the stomach arising after successful treatment of gastric MALT lymphoma in patients with autoimmune disease. Scand J Gastroenterol; 2003 Mar;38(3):294-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early cancer of the stomach arising after successful treatment of gastric MALT lymphoma in patients with autoimmune disease.
  • BACKGROUND: Extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma) arises in lymphoid tissue acquired through chronic antigenic stimulation as exemplified by Helicobacter pylori.
  • Secondary development of gastric cancer, however, is thought to be a rare event.
  • The detection of a signet ring cell carcinoma during follow-up endoscopy after successful therapy of MALT lymphoma in a patient with Sjögren's syndrome prompted us to analyse the frequency of subsequent gastric cancer in patients with underlying autoimmune disease (AD).
  • METHODS: Patients with early stage MALT lymphoma and an underlying AD were evaluated for the occurrence of a secondary gastric cancer during the course of follow-up.
  • Data analysed included the type of AD, stage of MALT lymphoma, H. pylori status, treatment for MALT lymphoma and response, follow-up, the presence of a secondary cancer, and time to development of cancer.
  • In all patients, histologic samples were reassessed for the extent of gastritis, presence of intestinal metaplasia or focal atrophy at the time of lymphoma diagnosis.
  • RESULTS: A total of eight patients with overt AD at the time of diagnosis of MALT lymphoma were identified.
  • All patients had early stage MALT lymphoma restricted to the mucosa and submucosa at the time of diagnosis, and the presence of H. pylori was found in all cases.
  • Two of these patients achieved complete remission (CR) of the lymphoma following H. pylori eradication, while six were judged unresponsive and underwent chemotherapy, resulting in CR in all cases.
  • One patient died from stroke while being in CR for 2 months following chemotherapy.
  • Two patients (25%) developed early cancer limited to the gastric mucosa while being in CR from lymphoma for 9 and 27 months, respectively, and underwent partial gastrectomy.
  • Final staging of gastric cancer revealed pT1pN0M0 in both cases.
  • In the remaining 4 patients, no evidence of lymphoma recurrence or a second malignancy has been found so far by regular follow-up every 3 months for a time-span between 52 and 63 months after initial diagnosis.
  • CONCLUSION: Patients with concurrent MALT lymphoma and an underlying autoimmune condition show not only an impaired response to H. pylori eradication but might also be at increased risk for the development of gastric cancer.
  • [MeSH-major] Autoimmune Diseases / therapy. Gastric Mucosa / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Aged. Antineoplastic Combined Chemotherapy Protocols. Austria. Biopsy. Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / therapy. Endosonography. Female. Follow-Up Studies. Humans. Metaplasia. Middle Aged. Neoplasm Staging. Polymyalgia Rheumatica / diagnosis. Polymyalgia Rheumatica / therapy. Pyloric Antrum / pathology. Remission Induction. Severity of Illness Index. Sjogren's Syndrome / diagnosis. Sjogren's Syndrome / therapy. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12737445.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


23. Lee SH, Choi WC, Kim KS, Park JW, Lee SH, Yoon SW: Shrinkage of gastric cancer in an elderly patient who received Rhus verniciflua Stokes extract. J Altern Complement Med; 2010 Apr;16(4):497-500
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shrinkage of gastric cancer in an elderly patient who received Rhus verniciflua Stokes extract.
  • PATIENT AND METHOD: We present here the case of a female patient (82 years old) with an adenocarcinoma of the stomach that was first diagnosed via an abdomen computed tomography (CT) scan and endoscopic biopsy.
  • Any conventional therapy such as surgical resection was not performed because of her advanced age.
  • COURSE OF THERAPY AND RESULTS: Daily therapy with 900 mg of orally administered RVS extract was initiated on September 25, 2006.
  • Five (5) months later, the gastroscopy and abdomen CT scan showed a marked decrease in the polypoid mass at the mid body and a slight decrease in the flat elevated lesion at the prepyloric antrum, as compared to tumor sizes on the first gastroscopy and abdomen CT scan.
  • She is alive and doing well at the present time (April 2009).
  • CONCLUSIONS: We suggest that RVS extract could be a candidate for a natural agent that induces selective apoptosis and inhibits cell growth in gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Flavonoids / therapeutic use. Phytotherapy. Plant Extracts / therapeutic use. Rhus. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20423218.001).
  • [ISSN] 1557-7708
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Plant Extracts
  •  go-up   go-down


24. Mimatsu K, Oida T, Kuboi Y, Kawasaki A, Kanou H, Kaneda H, Amano S: A long-surviving patient with unresectable advanced gastric cancer responding to S-1 after receiving improved gastrojejunostomy. Int J Clin Oncol; 2004 Jun;9(3):193-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-surviving patient with unresectable advanced gastric cancer responding to S-1 after receiving improved gastrojejunostomy.
  • Conventional gastrojejunostomy has been employed for unresectable advanced gastric cancer with pyloric stenosis; however, it is often not fully effective.
  • We report a patient with unresectable gastric cancer who was effectively treated with an anticancer drug, S-1, after receiving an improved gastrojejunostomy.
  • Upper gastrointestinal endoscopy showed a Borrmann III tumor in the antrum of the stomach, and gastric roentgenography showed pyloric stenosis.
  • A curative operation was impossible for the advanced gastric cancer.
  • She started treatment with 80 mg/day of S-1, given orally, for 28 days, followed by 14 days' rest, as 1 course.
  • During 16 courses of the treatment, she maintained a performance status of 0 to 1 and maintained quality of life.
  • This case suggested that the improved gastrojejunostomy was a useful method for treating unresectable gastric cancer, allowing the possibility of oral intake, and the use of S-1.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Anastomosis, Surgical. Drug Combinations. Female. Humans. Jejunum / surgery. Middle Aged. Palliative Care. Stomach / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15221605.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


25. Katsumata D, Sasaki K, Miyachi K, Joujima T, Tsumuraya M, Onodera S, Shimoda W, Yoda N, Ohkawa T, Odaka N, Kaneko H, Sunagawa M: [A case of effective treatment of oral TS-1 and intravenous MMC administration for multiple metastases of gastric cancer]. Gan To Kagaku Ryoho; 2004 Jul;31(7):1083-5
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of effective treatment of oral TS-1 and intravenous MMC administration for multiple metastases of gastric cancer].
  • A 49-year old man underwent distal gastrectomy (D3) for circumferential type 3 cancer at the gastric antrum and cholecystectomy in September 2002.
  • In conclusion, a combination of TS-1/MMC may be regarded as one option for postoperative adjuvant chemotherapy for outpatients.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Chemotherapy, Adjuvant. Drug Administration Schedule. Drug Combinations. Humans. Injections, Intravenous. Male. Middle Aged. Mitomycin / administration & dosage. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15272590.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 50SG953SK6 / Mitomycin; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


26. Bang YJ, Kang WK, Kang YK, Kim HC, Jacques C, Zuber E, Daglish B, Boudraa Y, Kim WS, Heo DS, Kim NK: Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol; 2002 Jul;32(7):248-54
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial.
  • OBJECTIVE: The aim of the present study was to confirm the efficacy and tolerability of docetaxel 75 mg/m(2) in a population of Korean patients with advanced gastric cancer.
  • METHODS: Patients with metastatic or locally recurrent gastric cancer received docetaxel 75 mg/m(2) by intravenous infusion every 3 weeks.
  • Most showed adenocarcinomas of the gastric antrum and/or body of the stomach.
  • A total of 159 cycles (median three cycles) were administered, with mean duration of treatment 10.9 weeks.
  • CONCLUSION: This study suggests that docetaxel 75 mg/m(2) is active in metastatic or locally recurrent adenocarcinoma with a low incidence of grade 3-4 adverse events.
  • Docetaxel warrants further study in combination regimens for advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Paclitaxel / analogs & derivatives. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy. Taxoids
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Drug Evaluation. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neutropenia / chemically induced

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12324575.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


27. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G: The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter; 2007 Nov;12 Suppl 2:32-8
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis.
  • BACKGROUND: Helicobacter pylori infection is a crucial factor in the multistep carcinogenic process of gastric cancer.
  • In this process the gastric mucosa evolves through the stages of acute gastritis, chronic gastritis, gastric atrophy (GA), and intestinal metaplasia (IM) before developing gastric adenocarcinoma.
  • AIMS: The main aim of this study was to systematically review the long-term effects of H. pylori eradication on gastric histology (i.e. effects on GA and IM for both antrum and corpus) by meta-analyzing all relevant studies.
  • RESULTS: For antrum GA the pooled OR with 95% CI was 0.554 (0.372-0.825), p=0.004.
  • For antrum IM the pooled OR was 0.795 (0.587-1.078), p=0.14.
  • [MeSH-major] Gastric Mucosa / pathology. Helicobacter Infections / drug therapy. Helicobacter Infections / pathology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991174.001).
  • [ISSN] 1083-4389
  • [Journal-full-title] Helicobacter
  • [ISO-abbreviation] Helicobacter
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


28. Ishido K, Koizumi W, Tanabe S, Higuchi K, Sasaki T, Katada C, Azuma M, Saigenji K, Futawatari N, Saegusa M: A patient with stage IV type 4 advanced gastric cancer who had a complete pathological response to short-term treatment with S-1 alone. Anticancer Drugs; 2008 Oct;19(9):921-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with stage IV type 4 advanced gastric cancer who had a complete pathological response to short-term treatment with S-1 alone.
  • Stage IV (cT3, cN3, cH0, cM1) type 4 advanced gastric cancer was diagnosed.
  • During the first course of treatment, grade 2 anorexia, grade 2 vomiting, and grade 2 diarrhea developed.
  • Treatment with S-1 was therefore discontinued on day 27.
  • There was marked narrowing of the pyloric antrum.
  • Abdominal computed tomography revealed that ascites and enlargement of the left adrenal gland and paragastric lymph nodes had resolved.
  • The primary gastric tumor, resected lymph nodes, and a peritoneal-lavage specimen were all negative for tumor.
  • [MeSH-major] Adenocarcinoma / diet therapy. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged, 80 and over. Drug Combinations. Female. Gastrectomy. Humans. Lymph Node Excision. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18766007.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


29. Xiao F, Crissey MA, Lynch JP, Kaestner KH, Silberg DG, Suh E: Intestinal metaplasia with a high salt diet induces epithelial proliferation and alters cell composition in the gastric mucosa of mice. Cancer Biol Ther; 2005 Jun;4(6):669-75
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal metaplasia with a high salt diet induces epithelial proliferation and alters cell composition in the gastric mucosa of mice.
  • Intestinal metaplasia of the gastric mucosa is an important component in the pathway to adenocarcinoma.
  • The mechanisms that induce the progression from intestinal metaplasia to cancer have not been elucidated.
  • High dietary salt has been known as one of the risk factors for gastric cancer development in humans.
  • Therefore, we investigated the role of high salt diet on gastric epithelial cell proliferation and differentiation, using our mouse model that ectopically expressed Cdx2 homeodomain transcription factor and induced an intestinal metaplastic phenotype in the gastric epithelia.
  • Sixty Cdx2 transgenic and sixty age-matched wild-type littermates were studied.
  • Fifty-percent Cdx2 transgenic and wild type mice were administered a high-salt diet and the other fifty-percent was fed a standard diet starting at 12 weeks after birth.
  • Cell types and cell kinetics were assessed by immunohistochemistry.
  • At 52 weeks, significant alterations in pathology were observed in the Cdx2 transgenic mice fed a high-salt diet, including elongation of gastric pits, reduction of the glandular zone in the gastric corpus, and deepening of glands in the antrum.
  • In the Cdx2 transgenic mice fed a high salt diet, the parietal and chief cells were significantly decreased in the gastric corpus.
  • A significant increase in cell proliferation and apoptosis in the corpus and antrum were observed in Cdx2 transgenic mice fed a high-salt diet as compared to wild-type littermates.
  • Taken together, these data implicate that intestinal metaplasia in concert with a high-salt diet induces epithelial proliferation, apoptosis, and alters cellular types in the gastric mucosa of mice.
  • Alteration in the composition of the gastric epithelium may play a role in influencing the microenvironment to engender susceptibility to carcinogens.
  • [MeSH-major] Gastric Mucosa / pathology. Intestine, Small / pathology. Sodium Chloride, Dietary / administration & dosage
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blotting, Western. Cell Differentiation / drug effects. Cell Lineage. Cell Proliferation / drug effects. Homeodomain Proteins / physiology. Immunohistochemistry. Metaplasia. Mice. Mice, Transgenic. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factors / physiology

  • MedlinePlus Health Information. consumer health - Sodium.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15970710.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / P30-DK-50306; United States / NIDDK NIH HHS / DK / R01-DK46704; United States / NIDDK NIH HHS / DK / R01-DK59539
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdx2 protein, mouse; 0 / Homeodomain Proteins; 0 / Sodium Chloride, Dietary; 0 / Transcription Factors
  •  go-up   go-down


30. Ma J, Kimura W, Takeshita A, Hirai I, Moriya T, Mizutani M: Neuroendocrine carcinoma of the stomach with peripancreatic lymph node metastases successfully treated with pancreaticoduodenectomy. Hepatogastroenterology; 2007 Oct-Nov;54(79):1945-50
Hazardous Substances Data Bank. TITANIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An upper gastrointestinal endoscopy revealed a 4x4-cm fungating tumor with its fundus locating mainly in the duodenal bulbus and extending to the gastric antrum, and tumor biopsy revealed the histological findings of adenocarcinoma.
  • Computed tomography (CT) showed a large mass in the duodenal bulbus with regional lymph node metastases.
  • The patient's disease was diagnosed as primary duodenal cancer with regional lymph node metastases preoperatively.
  • Histopathologically, the origin of the primary tumor was considered as a gastric origin, and the tumor was composed of diffused small cells with a moderate mitotic index and occasional rosette formation.
  • Adjuvant chemotherapy with TS-1 was administered on an out-patient basis 6 weeks after the operation.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Duodenum / pathology. Endoscopy, Gastrointestinal. Humans. Immunohistochemistry. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Pancreaticoduodenectomy. Silicates / therapeutic use. Titanium / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251134.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Silicates; 12067-57-1 / titanium silicide; D1JT611TNE / Titanium
  •  go-up   go-down






Advertisement